QS-GVK BIO's Schizophrenia Clinical Trial Outcomes Database
Dear All,
GVK BIO in collaboration with Quantitative Solutions (QS), have developed
Schizophrenia Clinical Trial Outcome Database. The database captures summary
level data for the clinical safety and efficacy outcomes from publicly
available data sources (Journal publications, Clinical trial registries,
Conference posters, Regulatory reviews, etc.).
The database includes clinical safety and efficacy information on both
second-generation antipsychotics (SGAs) currently approved or in development
for the first-line monotherapy treatment of schizophrenia and on
anti-psychotics used for the second-line treatment (monotherapy or add-on) in
treatment-resistant or refractory schizophrenia patients. Information on
first-generation antipsychotics (FGAs) such as haloperidol are included if they
were used as active controls.
To give a brief summary of the content:
Parameter
Description
Format
Excel
Indications
Schizophrenia
#Trials/References
114/128
# Patients
28,955
# Rows of Data
13,708
Last Updated
Sept, 2010*
Compounds
risperidone, paliperidone, quetiapine, ziprasidone, asenapine, aripiprazole,
olanzapine, chlorpromazine, haloperidol, sertindole, clozapine, iloperidone,
remoxipride, zotepine, cariprazine, methotrimeprazine, zotepine, fluoxetine,
sulpiride, estradiol, mirtazapine, fluvoxamine, fluphenazine,ginkgo biloba,
dehydroepiandrosterone, celecoxib, perphenazine, lamotrigine, CX516, donepezil,
LY2140023, selegiline, amisulpride, ritanserin, pregnenolone and lurasidone.
Key efficacy end points
PANSS, BPRS, BPRSd, CGI, GAF, SANS, NSA-16, Response, Relapse
Key safety end points
ESRS, SAS, AIMS, BARS, SWN, adverse event percentages, and treatment
discontinuations/required medication
*The first version 1.0 was released last September 2009, and the Database was
updated in September 2010, version 2.0.
Key Advantages:
· Models derived from Database can be used to characterize the
probability distribution of clinical efficacy and tolerability as a function of
various treatment and patient factors.
· The database can help companies conduct comparative efficacy and
safety analysis, link/scale biomarkers to clinical outcomes, predict/improve
trial outcome, and develop product differentiation strategies.
· The database is supported by customization and M&S consulting
services provided by GVK Bio and QS, respectively, to ensure maximum
flexibility and benefits to our clients
· Kindly revert back for any further details on the Database and its
utility
Kindly revert back for any further details on the Database and its utility
Best regards,
Satish
Satish Patil
Manager, Sales & Marketing
GVK Biosciences Pvt. Ltd., S-1, Phase-1,
Technocrats Industrial Estate, Balanagar, Hyderabad - 500 037
Ë+91-9177991172 | ': 040-40212953 | *:
[email protected]<mailto:[email protected]>
Notice: The information contained in this electronic mail message is intended
only for the use of the designated recipient. This message is privileged and
confidential. and the property of GVK BIO or its affiliates and subsidiaries.
If the reader of this message is not the intended recipient or an agent
responsible for delivering it to the intended recipient, you are hereby
notified that you have received this message in error and that any review,
dissemination, distribution, or copying of this message is strictly prohibited.
If you have received this communication in error, please notify us immediately
by telephone +91-40-66929999 and destroy any and all copies of this message in
your possession (whether hard copies or electronically stored copies).